

## MARKSANS PHARMA LIMITED

Regd. Office: 601-622, Chintamani Plaza, Mohan Studio Compd, A.K.Road, Andheri [East], Mumbai-400099

\_\_UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2007

Rs.in Lacs

_		<del>_</del>				
		Quarter ended		Half Year Ended		Previous Year ended
		30th Sep. 07	30th Sep 06	30th Sep. 07	30th Sep 06	31st March 07
Sr.	PARTICULARS	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(AUDITED)
1	Net sales /Income from Operations	5,440.83	7,139.70	10,204.91	14,184.54	23,988.74
2	Other Income	195.67	369.61	396.42	644.87	1,050.29
3	Total Expenditure	4,721.70	6,203.11	8,884.99	12,333.16	22,200.74
	-(Increase) /Decrease in Stock in trade	(593.14)	(212.18)	(596.05)	(644.85)	(4,067.93)
	-Consumption of Raw Material	3,788.84	5,174.51	6,504.68	10,574.73	20,278.35
	-Staff Cost	376.22	295.07	741.13	517.33	1,375.71
	-Other Expenditure	1,149.78	945.71	2,235.24	1,885.95	4,614.62
4	Interest	361.47	273.64	698.87	527.59	1,149.80
5	Depreciation	203.81	323.44	405.26	536.63	732.32
6	Profit/(Loss) before Tax	349.53	709.12	612.21	1,432.03	956.17
7	Provision for Taxation	0.69	125.00	35.69	270.00	421.98
8	Net Profit /(Loss)	348.84	584.12	576.52	1,162.03	534.18
9	Add/Less :Short/Exess provision/	-	-		-	158.41
	Prior period expenses	-	-	-	-	-
10	Net Profit/(Loss) after extra ordinary items	348.84	584.12	576.52	1,162.03	692.59
11	Paid up Equity Share Capital	-	-		-	
	(Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus	-	-		-	-
	( Excluding Revaluation Reserve)	-	-		-	
13	Basic and Diluted EPS for the period	0.97	1.63	1.60	3.23	1.93
	(Not annualised)	-	-		-	
14	Non -Promoter share holding	-	-		-	
	-Number of Shares	18,776,527	18,778,527	18,776,527	18,778,527	18776527
	-Percentage of Share holding	52.24%	52.25%	52.24%	52.25%	52.24%

## Notes:

- 1 The above results were taken on records at the meeting of the Board of Directors held on 31-10-2007
- 2 The details of investor complaints during the quarter is as under:
  - Opening Balance: NIL, Received during the quarter:1, Pending as on 30.09.07: NIL
- 3 The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- 4 Information on Consolidated Figures for the Half Year ended (i) Turnover: Rs 10,553.86 Lacs (ii) PAT: Rs.658 Lacs (iii) EPS: Rs.1.83 Basic
- 5 Previous year's figures have been re-grouped/re-classified, whereever necessary, so as to make them comparable with the current year's figures.

For MARKSANS PHARMA LIMITED

Place: Mumbai

Date: 31st October 2007

MARK SALDANHA Managing Director